Associations among obesity, acute weight gain, and response to treatment with Olanzapine in adolescent schizophrenia

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 8, 2013, Pages 522-530

  Kemp, David E ^a   Correll, Christoph U ^b   Tohen, Mauricio ^c   Delbello, Melissa P ^d   Ganocy, Stephen J ^a   Findling, Robert L ^e   Chang, Kiki ^f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

ADOLESCENT; ARTICLE; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; BRIEF PSYCHIATRIC RATING SCALE FOR CHILDREN; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DSM-IV; FEMALE; HOSPITALIZED ADOLESCENT; HUMAN; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBESITY; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MODELS, STATISTICAL; OBESITY; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEX CHARACTERISTICS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84886057408     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0099     Document Type: Article

References (59)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Andreasen NC, Carpenter Jr. WT, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449, 2005.
3. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ: Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 5:3, 2005a.
4. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ: Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol 19 Suppl 6:110-117, 2005b.
5. Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P: Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 163:1276-1279, 2006.
6. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62:231-238, 2001.
7. Bustillo JR, Buchanan RW, Irish D, Breier A: Differential effect of clozapine on weight: A controlled study. Am J Psychiatry 153:817-819, 1996.
8. Correll CU: Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69 Suppl 4:26-36, 2008.
9. Correll CU, Lencz T, Malhotra AK : Antipsychotic drugs and obesity. Trends Mol Med 17:97-107, 2011.
10. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
11. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA: Antipsychoticinduced weight gain and therapeutic response: A differential association. J Clin Psychopharmacol 22:244-251, 2002.
12. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114-126, 2011.
13. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ: Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 7:424-430, 2005.
14. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E: Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 160:112-117, 2003.
15. Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S: Efficacy and safety of quetiapine in adolescents with schizophrenia: a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 22:327-342, 2012.
16. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008.
17. Fitzmaurice GM, Laird NM, Ware JH: Applied Longitudinal Analysis. Hoboken, NJ: Wiley; 2004.
18. Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, Lieberman JA, Sikich L: Treatment of early-onset schizophrenia spectrum disorders (TEOSS): Demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 46:979-988, 2007.
19. Gillberg IC, Hellgren L, Gillberg C: Psychotic disorders diagnosed in adolescence. Outcome at age 30 years. J Child Psychol Psychiatry 34:1173-1185, 1993.
20. Goldstein BI, Birmaher B, Axelson DA, Goldstein TR, Esposito-Smythers C, Strober MA, Hunt J, Leonard H, Gill MK, Iyengar S, Grimm C, Yang M, Ryan ND, Keller MB: Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry 69:1953-1959, 2008.
21. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF: A 6-week, randomized, double-blind, placebocontrolled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611-621, 2009.
22. Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ: Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry 65:1679-1687, 2004.
23. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R: The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 128:166-170, 2011.
24. Hummer M, Kemmler G, Kurtz M, Kurtzthaler I, Oberbauer H, Fleischhacker WW: Weight gain induced by clozapine. Eur Neuropsychopharmacol 5:437-440, 1995.
25. Johnsen E, Jrgensen HA: Effectiveness of second generation antipsychotics: A systematic review of randomized trials. BMC Psychiatry 8:31, 2008.
26. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
27. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276, 1987.
28. Keepers GA, Clappison VJ, Casey DE: Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113-1117, 1983.
29. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR: Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 12:404-413, 2010.
30. Kloiber S, Ising M, Reppermund S, Horstmann S, Dose T, Majer M, Zihl J, Pfister H, Unschuld PG, Holsboer F, Lucae S: Overweight and obesity affect treatment response in major depression. Biol Psychiatry 62:321-326, 2007.
31. Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D: Assessment of child and adolescent overweight and obesity. Pediatrics 120 Suppl 4:S193-228, 2007.
32. Krishnamoorthy J, King BH: Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 8:107-13, 1998.
33. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M: Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60-70, 2009a.
34. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW: The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 70:247-58, 2009b.
35. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S: Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34:60-71, 2008.
36. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M: Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149:68-72, 1992.
37. Maloney AE, Sikich L: Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatr Dis Treat 6:749-66, 2010.
38. Masi G, Liboni F: Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs 71:179-208, 2011.
39. Mathews J, Newcomer JW, Mathews JR, Fales CL, Pierce KJ, Akers BK, Marcu I, Barch DM: Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry 69:1226-1237, 2012.
40. McClellan J, McCurry C, Snell J, DuBose A: Early-onset psychotic disorders: Course and outcome over a 2-year period. J Am Acad Child Adolesc Psychiatry 38:1380-1388, 1999.
41. Meltzer HY, Perry E, Jayathilake K: Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59:19-27, 2002.
42. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA: The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 80:9-18, 2005.
43. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM: Prevalence of high body mass index in US children and adolescents, 2007-2008.JAMA 303:242-249, 2010.
44. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006.
45. Overall JE, Pfefferbaum B: The Brief Psychiatric Rating Scale for Children. Psychopharmacol Bull 18:10-16, 1982.
46. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343, 2002.
47. Rauser L, Savage JE, Meltzer HY, Roth BL: Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine (2C) receptor. J Pharmacol Exp Ther 299:83-89, 2001.
48. Roerig JL, Steffen KJ, Mitchell JE: Atypical antipsychotic-induced weight gain: Insights into mechanisms of action. CNS Drugs 25:1035-1059, 2011.
49. Ross RG, Heinlein S, Tregellas H: High rates of comorbidity are found in childhood-onset schizophrenia. Schizophr Res 88:90-95, 2006.
50. Ross RG, Novins D, Farley GK, Adler LE: A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13:301-309, 2003.
51. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431, 2008.
52. Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D: A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 70:1179-1187, 2011.
53. Singh MM, De Dios LV, Klein NS: Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics 11:562-570, 1970.
54. Stroup TS, McEvoy JP, Ring KD, Hamer RH, Lavange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA, the Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry 168:947-956, 2011.
55. Theisen FM, Linden A, Geller F, Schafer H, Martin M, Remschmidt H, Hebebrand J: Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 35:339-345, 2001.
56. Thompson WK, Kupfer DJ, Fagiolini A, Scott JA, Frank E: Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: Analysis of acute phase data from a randomized controlled trial. J Clin Psychiatry 67: 783-788, 2006.
57. Umbricht DS, Pollack S, Kane JM: Clozapine and weight gain. J Clin Psychiatry 55(Suppl B):157-160, 1994.
58. Werry JS, McClellan JM, Andrews LK, Ham M: Clinical features and outcome of child and adolescent schizophrenia. Schizophr Bull 20:619-630, 1994.
59. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D: The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143:35-3n9, 1986.